Free Trial

Moleculin Biotech (MBRX) Competitors

Moleculin Biotech logo
$0.35 +0.00 (+0.72%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$0.35 0.00 (0.00%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBRX vs. LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, PMN, and GOVX

Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry.

Moleculin Biotech vs. Its Competitors

Moleculin Biotech (NASDAQ:MBRX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

In the previous week, Moleculin Biotech and Moleculin Biotech both had 1 articles in the media. Moleculin Biotech's average media sentiment score of 1.11 beat Lipocine's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moleculin Biotech
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lipocine
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lipocine has higher revenue and earnings than Moleculin Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moleculin BiotechN/AN/A-$21.76MN/AN/A
Lipocine$11.20M1.56$10K-$1.02-3.21

Moleculin Biotech currently has a consensus target price of $4.00, suggesting a potential upside of 1,042.86%. Lipocine has a consensus target price of $9.00, suggesting a potential upside of 175.23%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Lipocine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moleculin Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lipocine
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lipocine's return on equity of -26.68% beat Moleculin Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Moleculin BiotechN/A -278.80% -100.11%
Lipocine N/A -26.68%-24.77%

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 1.9% of Moleculin Biotech shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Moleculin Biotech has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Summary

Lipocine beats Moleculin Biotech on 5 of the 9 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBRX vs. The Competition

MetricMoleculin BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.80M$2.91B$5.56B$9.03B
Dividend YieldN/A2.44%5.22%3.99%
P/E RatioN/A21.5627.6920.25
Price / SalesN/A241.84389.53161.89
Price / CashN/A42.7336.8958.10
Price / Book0.207.518.035.67
Net Income-$21.76M-$55.14M$3.18B$249.21M
7 Day Performance12.11%4.61%2.93%3.28%
1 Month Performance-47.76%0.90%1.72%3.95%
1 Year Performance-89.97%5.40%34.39%20.98%

Moleculin Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBRX
Moleculin Biotech
3.1547 of 5 stars
$0.35
+0.7%
$4.00
+1,042.9%
-90.0%$4.80MN/A0.0020Positive News
LPCN
Lipocine
1.5916 of 5 stars
$3.16
-4.0%
$9.00
+184.8%
-55.1%$17.60M$11.20M-3.1010
CING
Cingulate
2.2986 of 5 stars
$4.07
+0.5%
$26.00
+538.8%
+1,157.3%$17.19MN/A-0.4820Positive News
MTEX
Mannatech
0.2743 of 5 stars
$9.35
+3.9%
N/A+25.8%$17.11M$117.87M-93.50250High Trading Volume
GELS
Gelteq
N/A$1.73
-4.4%
N/AN/A$17.08M$100K0.00N/ANews Coverage
Gap Up
CARM
Carisma Therapeutics
1.8566 of 5 stars
$0.39
-2.2%
$1.93
+391.6%
-64.7%$16.74M$19.63M-0.2520News Coverage
Gap Up
MRKR
Marker Therapeutics
3.2041 of 5 stars
$1.53
+4.8%
$13.17
+760.6%
-68.3%$16.52M$6.59M-1.1560Positive News
Gap Up
CTXR
Citius Pharmaceuticals
2.4277 of 5 stars
$1.59
+3.9%
$53.00
+3,233.3%
-83.4%$16.27MN/A0.0020High Trading Volume
RVPH
Reviva Pharmaceuticals
2.2779 of 5 stars
$0.38
+12.9%
$9.00
+2,261.6%
-68.5%$16.20MN/A-0.485News Coverage
Gap Up
High Trading Volume
PMN
Promis Neurosciences
3.3904 of 5 stars
$0.48
+0.7%
$4.50
+830.1%
-74.1%$15.70MN/A-9.685Gap Up
GOVX
GeoVax Labs
3.3474 of 5 stars
$0.87
-9.8%
$11.10
+1,182.2%
-82.9%$15.29M$3.95M-0.2410Analyst Downgrade
Gap Up

Related Companies and Tools


This page (NASDAQ:MBRX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners